Trxade Group Signs Agreement to Distribute Glaucoma Drug in U.S.

TAMPA, Fla., Nov. 30, 2015, TRXD, OTCQB, (GLOBE NEWSWIRE) Trxade Group, Inc., (OTCQB:TRXD) a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, today announced that its wholly-owned subsidiary, Westminster Pharmaceuticals LLC ( Westminster ) has launched Brimonidine Tartrate Ophthalmic Solution 0.2% as part of an exclusive agreement with Indoco Remedies, LTD. (BSE Listed Ticker Symbol: INDOCO). Brimonidine Tartrate Ophthalmic Solution 0.2% is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension patients and will be marketed under the Westminster Pharmaceuticals, LLC brand. For the year ended December 31st, 2014, Brimonidine Tartrate Ophthalmic Solution 0.2% generated sales of approximately $6.8 million, according to IMS Health data. Under the terms of the exclusive supply and distribution agreement, Indoco Remedies will manufacture an
http://bit.ly/1Tgi2Yp

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: